caa a22 4500 445335521 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1695-2 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1695-2 Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays [Elektronische Daten] [Kab Kim, Young Koh, Heung-Moon Chang, Tae Kim, Jeong Yook, Byung Kim, Se Jang, Young Park] Background: Recent advances in molecular targeted therapy have identified HER2 as an important target for anti-cancer therapy in gastric cancer (GC). Although the clinical relevance and prognostic significance of HER2 in breast cancer has been well acknowledged, it remains controversial in GC. Methods: HER2 expression was investigated in two independent series of GC by immunohistochemical staining. One series corresponded to 1,414 cases of whole-tissue sections and the other corresponded to 595 cases of tissue microarrays (TMAs). Results were compared and correlated with clinicopathologic parameters. Results: HER2-positivity was detected in 12.3% of whole-tissue sections and 17% of TMAs. Among samples scored 3+, 90.1% stained ≥50% of the tumor area, but only 40.9% in score 2+ cases stained ≥50% of the tumor area. In whole-tissue sections, HER2-positivity was correlated with age (P=0.002), histological type (differentiated or intestinal, P<0.001), lymphovascular invasion (P=0.005), and lymph node metastasis (P=0.009). In TMAs, HER2-positivity was correlated only with age (P=0.003) and histological type (P<0.001). Multivariate analyses of the differentiated GC subgroup revealed that HER2-positivity was an independent poor prognostic factor (P=0.042). The cases with HER2-positive in ≥50% of the tumor area showed worse prognosis than those of <50% (P=0.021). Conclusions: Despite discrepancies in the results from whole-tissue sections and TMAs, HER2 overexpression was positively correlated with aggressive biological behavior and was an independent poor prognostic factor for recurrence in differentiated GCs. Therefore, HER2-positive GCs should be considered for adjuvant trastuzumab therapy. Society of Surgical Oncology, 2011 Kim Kab Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Koh Young Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Chang Heung-Moon Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Kim Tae Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Yook Jeong Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Kim Byung Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Jang Se Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Park Young Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2833-2840 1068-9265 18:10<2833 2011 18 10434 https://doi.org/10.1245/s10434-011-1695-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1695-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kim Kab Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Koh Young Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Chang Heung-Moon Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Kim Tae Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Yook Jeong Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Kim Byung Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Jang Se Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 700 1- Park Young Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2833-2840 1068-9265 18:10<2833 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer